Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
anakinra
Swedish Orphan Biovitrum AB (publ)
L04AC03
anakinra
Immunosuppressants
Arthritis, Rheumatoid; COVID-19 virus infection
Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs).
Revision: 34
Authorised
2002-03-08
29 B. PACKAGE LEAFLET 30 PACKAGE LEAFLET: INFORMATION FOR THE USER KINERET 100 MG/0.67 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Anakinra READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Kineret is and what it is used for 2. What you need to know before you use Kineret 3. How to use Kineret 4. Possible side effects 5. How to store Kineret 6. Contents of the pack and other information 1. WHAT KINERET IS AND WHAT IT IS USED FOR Kineret contains the active substance anakinra. This is a type of cytokine (an immunosuppressive agent) that is used to treat: - Rheumatoid Arthritis (RA) - COVID-19 in patients who have pneumonia, need extra oxygen and are at risk of lung failure - Periodic fever syndromes: - Cryopyrin-Associated Periodic Syndromes (CAPS) o Neonatal-Onset Multisystem Inflammatory Disease (NOMID), also called Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), o Muckle-Wells Syndrome (MWS), o Familial Cold Autoinflammatory Syndrome (FCAS) - Familial Mediterranean Fever (FMF) - Still’s disease including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD) Cytokines are proteins made by your body that co-ordinate communication between cells and help control cell activity. In RA, CAPS, FMF, Still’s disease, and in COVID-19 pneumonia, your body produces too much of a cytokine called interleukin-1. This results in harmful effects leading to inflammation, causing the symptoms of the disease. Normally, your body produces a protein that b Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each graduated pre-filled syringe contains 100 mg of anakinra* per 0.67 ml (150 mg/ml). * Human interleukin-1 receptor antagonist (r-metHuIL-1ra) produced in _Escherichia coli _cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless-to-white solution for injection that may contain some product-related translucent- to-white amorphous particles. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rheumatoid Arthritis (RA) Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone. COVID-19 Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml (see sections 4.2, 4.4 and 5.1). Periodic fever syndromes Kineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above: _Cryopyrin-Associated Periodic Syndromes (CAPS) _ Kineret is indicated for the treatment of CAPS, including: - Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) - Muckle-Wells Syndrome (MWS) - Familial Cold Autoinflammatory Syndrome (FCAS) _Familial Mediterranean Fever (FMF) _ Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate. Still’s Disease Kineret is indicated in a Aqra d-dokument sħiħ